ACTICCA-1

ACTICCA-1: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma.
A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial.

Trial Overview and Summary

Chief Investigator: Henning Wege
UK National Coordinator:
John Bridgewater
Overall Sponsor: University Medical Center Hamburg-Eppendorf
UK Sponsor: University of Birmingham
UK Funder: Cancer Research UK
Disease Site: Liver and Gallbladder
Trial Type:  Clinical Trial of an Investigational Medicinal Product
Status: Open
UKCRN Study ID (if applicable): 173496
Open to New Sites? Yes
Overall Recruitment Start Date: Feb 2014 
UK Recruitment Start Date: 15 Mar 2016
Anticipated Recruitment End Date: September 2019
CRCTU Trial Management Team: A-Team
Trial Email Address: ACTICCA-01@trials.bham.ac.uk

 Trial Summary

 ACTICCA-1 is a clinical study comparing the ‘post-surgery’ treatment of patients who have had surgery to remove cholangiocarcinoma (cancer of bile ducts in the liver) or muscle invasive gall bladder carcinoma (gall bladder cancer). One set of patients will have 24 weeks of chemotherapy (gemcitabine and cisplatin) after their surgery and one set of patients will receive 24 weeks of capecitabine tablet chemotherapy.

The main thing being compared is how long both sets of patients survive without their cancer coming back. There is currently not much research looking at this.

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.

Trial Protocol

Please Note:
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website (see the link below).
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

More Information